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AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE
Autoimmune Acute Liver Failure: Proposed Clinical and
Histological Criteria
R. Todd Stravitz,1* Jay H. Lefkowitch,2* Robert J. Fontana,3 M. Eric Gershwin,4 Patrick S. C. Leung,4
Richard K. Sterling,1 Michael P. Manns,5 Gary L. Norman,6 William M. Lee,7 and the Acute Liver Failure Study Group
Identifying autoimmune hepatitis as the etiology of acute liver failure (ALF) is potentially
important, because administering corticosteroids might avoid the need for liver transplanta-
tion. However, clinical and histological criteria of autoimmune ALF (AI-ALF) have not been
defined. Liver sections (biopsies and explants) from a 72-patient subset of the ALF Study
Group Registry with indeterminate ALF were reviewed by a pathologist blinded to all clini-
cal data and were diagnosed with probable AI-ALF based on four features suggestive of an
autoimmune pathogenesis: distinctive patterns of massive hepatic necrosis (present in 42%
of sections), presence of lymphoid follicles (32%), a plasma cell–enriched inflammatory
infiltrate (63%), and central perivenulitis (65%). Forty-two sections (58%) were considered
probable for AI-ALF; this group demonstrated higher serum globulins (3.7 6 0.2 g/dL ver-
sus 3.0 6 0.2 g/dL; P 5 0.037) and a higher prevalence of antinuclear and/or anti–smooth
muscle antibodies (73% versus 48%; P 5 0.034) compared to those without histology sug-
gestive of probable AI-ALF. Thirty patients concordant for autoantibodies and probable AI-
ALF upon histological analysis were more likely to have the classical autoimmune hepatitis
phenotype (female predominance [72% versus 48%; P < 0.05], higher globulins [3.9 6
0.2 g/dL versus 3.0 6 0.2 g/dL; P < 0.005], and higher incidence of chronic hepatitis in
long-term follow-up [67% versus 17%, P5 0.019]) compared to the population without con-
cordant AI-ALF histology and autoantibodies. Conclusion: Patients with indeterminate ALF
often have features of autoimmune disease by histological analysis, serological testing, and
clinical recurrence during follow-up. In contrast to classical autoimmune hepatitis, histological
features of AI-ALF predominate in the centrilobular zone. (HEPATOLOGY 2011;53:517-526)
A
lthough autoimmune hepatitis (AIH) typically
presents as a chronic necroinflammatory liver
disease, an acute presentation occurs in up to
25%, a small minority of whom progress to autoim-
mune acute liver failure (AI-ALF).1 The diagnosis of
AIH has historically presented a challenge for clinicians
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but is of critical importance, because many patients will
have dramatic responses to the administration of cortico-
steroids.2 Diagnostic criteria for classical AIH have been
standardized by consensus, and have included histological,
demographic, and laboratory components, as well as the
absence of data suggestive of another diagnosis.3,4 How-
ever, these criteria were designed to differentiate AIH from
other causes of chronic liver disease, rather than to address
diagnostic considerations of ALF.
The etiology of ALF, the syndrome of abrupt liver
injury with ensuing coagulopathy and hepatic ence-
phalopathy, can be determined in the majority of
patients on the basis of a history of drug exposure, posi-
tive acute viral serology, or other historical feature (for
example, pregnancy, mushroom ingestion, malignancy,
or cardiovascular instability). However, the second most
common etiology of ALF after acetaminophen (N-ace-
tyl-p-aminophenol [APAP]) overdose is unknown or
indeterminate, representing approximately 20% of cases
in the U.S. Acute Liver Failure Study Group Registry.5
A small minority of patients with ALF of indeterminate
etiology have detectable protein-APAP adducts that sug-
gest a remote ingestion, but more than 80% remain
undiagnosed even after retrospective analysis of stored
specimens for occult viral infections. Some patients with
indeterminate ALF may be suspected of having an auto-
immune pathogenesis on the basis of positive autoanti-
bodies and other clinical clues (for example, female sex
and hyperglobulinemia). However, even in patients with
demographic and laboratory evidence of AIH, the diag-
nosis of AI-ALF usually remains tentative because auto-
antibodies are nonspecific, histology is usually not avail-
able, and the entity is so rare that diagnostic criteria
have not been codified by consensus. The histological
assessment of ALF is complicated further by the absence
of a formal microscopic classification system and the of-
ten-presumed nonspecificity of the changes comprising
massive hepatic necrosis (MHN).
We hypothesized that many patients with ALF of
indeterminate etiology have an autoimmune pathoge-
nesis resembling AIH. Small series have suggested that
the histological features of AIH presenting as an acute
hepatitis include centrilobular lesions6-12 similar to
those in liver allograft specimens from patients with
severe, ‘‘atypical,’’ acute cellular rejection.13,14 Accord-
ingly, we developed histological criteria on the basis of
these observations to identify patients with a likely
autoimmune pathogenesis, and compared their pre-
senting clinical and serological characteristics to those
without histological features of autoimmunity. Further-
more, because AIH can recur after liver transplanta-
tion, we hypothesized that those patients with histo-
logical features of autoimmunity would be more likely
to develop chronic hepatitis in their native livers if
they recovered from ALF, or to develop recurrent allo-
graft hepatitis after liver transplantation.
Patients and Methods
Patients and Follow-Up. The study population was
enrolled in the ALF Study Group Registry between
1998 and 2008. Entry criteria included ALF (coagul-
opathy [international normalized ratio {INR}  1.5]
and hepatic encephalopathy within 26 weeks of the
onset of illness, in a patient without previously recog-
nized liver disease).15 Study subjects were chosen from
a total registry of 1100 patients on the basis of having
an indeterminate evaluation for the etiology of ALF,
defined as: (1) no serologic evidence of acute viral hep-
atitis, (2) no evidence of ischemic liver injury (acute
Budd-Chiari syndrome or ‘‘shock liver,’’), and (3) no
evidence of drug-induced hepatotoxicity (history of
APAP overdose or recent prescription drug or over-
the-counter herbal exposure). Patients with suspected
acute Wilson disease or liver failure related to malig-
nancy or pregnancy were also excluded. These criteria
identified a subpopulation of 204 patients with ALF of
indeterminate etiology, some of whom had detectable
autoantibodies on admission and were thereby sus-
pected of having AIH. However, because autoantibod-
ies are often nonspecific, they were considered non-
diagnostic for the purposes of this study.
Attempts were made to recover liver samples from
each of 204 patients meeting the inclusion criteria
above. Records indicated that 61 subjects had neither
liver biopsies nor explant pathology available. Of the
143 potential samples, tissue was recovered from 79
(55%) for histological evaluation. Adequate liver tissue
for analysis was recovered in 72 cases (50% of total);
specimens from seven subjects were inadequate for
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diagnosis due to small size. Forty-six samples were
obtained from liver explants and 26 from transjugular
liver biopsies. Clinical and serological characteristics of
the 204 total patients and the subset of 72 with liver
tissue available were similar, suggesting that the latter
was a balanced subset of the former (data not shown).
Nineteen of 72 patients received corticosteroids for clin-
ically suspected AIH. However, due to small sample size
and lack of randomization, response to steroids could
not be analyzed as a diagnostic marker for AI-ALF.
Patients who survived ALF, either after spontaneous
recovery or liver transplantation, were requested to
return twice, at 12 and 24 months after the admis-
sion for ALF. Detailed medical history including labo-
ratory analysis results and liver biopsy results were
reviewed at each visit. Follow-up liver biopsies were
read locally for histological evidence of hepatitis and
rejection (in transplant recipients) by study site pathol-
ogists and were not retrieved for central reanalysis.
Methods and Statistical Analysis.
Histological Analysis. Samples of liver were eval-
uated in a blinded fashion on two occasions by an expe-
rienced hepatopathologist (J.H.L.). The first review was
a survey to identify features of an acute autoimmune
pathogenesis, as described.6-12 Particular attention was
paid to the centrilobular region of the lobule.8,9,11,12
The second review, performed blinded to the first
review, was undertaken to ensure reproducibility of the
findings and to further subclassify the types of MHN.
Concordance for finding in the first and second reviews
was 100% (data not shown).
During the first review, several variants of MHN
were observed and were classified as MHN1 to MHN5
in the second review (Figs. 1 and 2). Three patterns
(MHN1, MHN2, and MHN3) were considered rela-
tively nonspecific. MHN1 was characterized by classical
massive necrosis with near-complete loss of hepatocytes
throughout the lobules, residual intrasinusoidal in-
flammation, periportal neocholangiolar proliferation
(ductular reaction), and portal/periportal inflammation.
MHN2 was characterized by submassive necrosis, repre-
senting regions of MHN1 as well as regenerative nod-
ules and areas of early fibrosis, and was considered to
represent a more subacute clinical course than MHN1.
MHN3 demonstrated necroinflammatory changes of
acute hepatitis in portions of the specimen (spotty ne-
crosis) as well as other regions with more substantial
confluent necrosis, including areas of bridging hepatic
necrosis or multilobular necrosis with neocholangiolar
proliferation. Two patterns of MHN (types 4 and 5) were
Fig. 1. Diagrammatic depiction of five patterns of MHN. Normal hepatic architecture is depicted in the upper left diagram for comparison.
Areas of hatched blue represent necrotic hepatocytes and areas in light blue represent portal tracts.
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considered more characteristic of an autoimmune pathoge-
nesis. MHN4 showed the typical features of panlobular
necrosis, but with prominence of centrilobular necroin-
flammation and hemorrhage, resembling the severe form of
the centrilobular variant of AIH10-12 and the centrilobular
variant of acute cellular rejection observed in transplant
allografts.14,16 MHN5 showed features of classical peripor-
tal AIH in conjunction with superimposed changes of mas-
sive necrosis and sometimes centrilobular necroinflamma-
tion. In addition to patterns of MHN, three additional
features were considered supportive of an autoimmune
pathogenesis of liver injury: the presence of central perive-
nulitis (chronic inflammation, including lymphocytes and/
or plasma cells, in and around central veins), often accom-
panied by hepatocyte drop-out/necrosis14 (Fig. 3), the pres-
ence of plasma cells in the inflammatory infiltrate, and the
presence of portal tract lymphoid aggregates (evidence of a
chronic inflammatory process).
Simplified International Autoimmune Hepatitis
Group Criteria for AI-ALF. The diagnosis of AIH
has traditionally relied upon a clinicopathological
Fig. 2. Histological variants of MHN. (A) MHN type 1: ‘‘typical’’ MHN with panlobular necrosis and neocholangiolar proliferation (ductular reac-
tion) (arrows) emerging from parenchyma near portal tracts (PT). (B) MHN type 2: there is confluent necrosis in the field left of the hatched line,
with early regenerative nodules (N), a pattern also referred to as ‘‘submassive necrosis’’. (C) MHN type 3: acute hepatitis with lobular disarray,
inflammation, and liver-cell damage is seen at bottom and is separated by the hatched line from more severe confluent necrosis above.
(D) MHN type 4: centrilobular hemorrhagic necrosis superimposed on the general features of massive necrosis is prominent at low power. Inset:
one centrilobular region (arrow) shows lymphocytes and plasma cells around, infiltrating, and within the lumen of a central vein (‘‘central perive-
nulitis’’), in association with hemorrhage and hepatocyte loss. (E) MHN type 5: confluent necrosis is present superimposed on features of an
underlying chronic hepatitis, including portal lymphoid aggregates (LA) and interface hepatitis (IH). Note confluent bridging hepatic necrosis
(blue arrows) extending between central vein (CV) and portal tract at upper right. Multilobular necrosis is also present at the left of the field.
Magnifications: (A-E) Hematoxylin and eosin stain, 40. Inset to (D), hematoxylin and eosin stain, 200.
Fig. 3. Central perivenulitits. This section from an explanted liver
shows severe hepatitis with extensive inflammation extending from the
portal tract (PT) into the lobule, with marked loss of hepatocytes. Note
the prominent hepatocyte loss and inflammation around the central
vein (CV), ‘‘central perivenulitis.’’ (Inset) Higher magnification of central
perivenulitis highlighted by plasma cells surrounding and infiltrating
the vein wall, associated with marked hepatocyte destruction (hema-
toxylin and eosin stain).
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scoring system developed by the International Autoim-
mune Hepatitis Group (IAIHG),3 which was designed
to differentiate AIH from other chronic liver diseases.
More recently, Simplified Diagnostic Criteria (SDC)
for AIH have been proposed, which consist of points
awarded for histology, serum globulin concentration,
the absence of hepatitis viral markers, and the presence
of autoantibodies.4 In the SDC for AIH, histological
features are categorized as typical, compatible, and in-
compatible with AIH and awarded 2, 1, or 0 points,
respectively. For purposes of validating our proposed
histological features of AI-ALF using the SDC index,
we assigned a similar point system, using the overall
histological impression after the two reviews: 2 points
were awarded for probable AI-ALF, 1 point for compat-
ible with AI-ALF but with fewer autoimmune features,
and 0 points for incompatible with AI-ALF. Patients
were also given scores of up to 2 points each for auto-
antibodies and globulin concentration (upper limit of
the normal range was considered to be 3.5 g/dL); all
patients were automatically awarded 2 points, because
by inclusion criteria of the study, all had negative viral
serologies. Therefore, the simplified IAIHG criteria
modified for AI-ALF ranged from 2-8 points. By the
SDC for AIH,  6 points is considered suggestive of
AIH and  7 points is considered diagnostic of AIH.
Autoimmune Serologies. Antinuclear antibodies
(ANA) and anti–smooth muscle antibodies (ASMA)
were obtained at the time of study admission from the
laboratories of ALF Study Group sites in 168 (82%)
and 144 (71%) of the 204 patients, respectively. A
positive ANA and/or ASMA from local laboratories
was defined as detectable at a serial dilution of  1:40
titer; titers < 1:40 were defined as negative. Stored
sera from those patients without ANA/ASMA available
from local laboratories were analyzed at a later date in
a single laboratory, such that overall, ANA and ASMA
results were available from 94% and 93% of subjects,
respectively. A battery of additional autoimmune serol-
ogies were also determined for 109 (53%) patients by
enzyme-linked immunosorbent assay (QUANTA lite;
INOVA Diagnostics, Inc.) and bead-based (QUANTA
Plex; INOVA Diagnostics, Inc.) assays. For the 72
patients with liver tissue available for review, 61 (85%)
had sera retrospectively reevaluated for autoimmune
serologies. Assays were performed using recombinant
and native autoantigens as described.17
Statistical Analysis. Data are expressed as mean 6
standard error of the mean. Dichotomous variables
were analyzed for significance by chi-square test or
two-tailed Fisher’s exact test, as appropriate, and con-
tinuous variables by analysis of variance. Statistical
analysis was performed with JMP, version 8.0. A P 
0.05 was considered significant.
Results
Clinical Description of Study Population and
Prevalence of Histological Features of Autoimmu-
nity. Demographic and clinical characteristics of the
72-patient study population are shown in Table 1.
Patients were predominantly young (mean age, 41
years), female (58%), Caucasian (67%), and overweight
(mean BMI 30 kg/m2). Admission laboratory data
reflected severe hepatic dysfunction and frequent renal
dysfunction, with mean INR 3.4 6 0.2, bilirubin 24.7
6 1.3 mg/dL, and creatinine 1.8 6 0.3 mg/dL. Renal
insufficiency often became more severe after admission,
with a mean peak creatinine of 2.5 6 0.2 mg/dL. Sixty-
three percent of patients had anti-nuclear (ANA) and/or
anti-smooth muscle antibodies (ASMA), 8% anti-tissue
transglutaminase (tTG), 3% anti-liver/kidney microsome
(LKM) or anti-soluble liver antigen (SLA) antibodies,
and 15% anti-mitochondrial antibodies (AMA). The
overall survival of the population was 71%, but 60%
required liver transplantation; only 15% survived without
transplantation.
Table 1. Demographic and Clinical Characteristics and
Outcomes of the Study Population (N 5 72)
Clinical Parameter N (%)
Age (years) 41.0 6 1.7
Female sex 42 (58)
Caucasian race 48 (67)
Body mass index (kg/m2) 30.0 6 1.1
Jaundice-encephalopathy (days) 17 6 2
Hepatic encephalopathy grade 3/4 26 (39)
Creatinine (mg/dL)
Admission 1.8 6 0.2
Peak 2.5 6 0.2
INR 3.2 6 0.2
Alanine aminotransferase (IU/L) 1134 6 137
Aspartate aminotransferase (IU/L) 1231 6 197
Alkaline phosphatase (IU/L) 205 6 15
Total bilirubin (mg/dL) 24.7 6 1.3
Globulins (g/dL) 3.4 6 0.2
ANA 35 (50)
ASMA 24 (34)
ANA 6 ASMA 44 (63)
Anti-LKM or anti-SLA 2 (3)
Anti-tTG 5 (8)
AMA 10 (15)
Spontaneous survival 11 (15)
Liver transplantation 43 (60)
Overall survival 51 (71)
Unless specified, laboratory data refer to admission values. Spontaneous sur-
vival refers to transplant-free survival. Outcomes refer to cumulative rates 21
days from admission.
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The prevalence of the four proposed histological fea-
tures of autoimmunity, and the concurrence of these
features in the same liver specimen, is depicted in Ta-
ble 2. The most common feature of autoimmunity
was central perivenulitis (65%), followed by plasma
cell enrichment (63%), an autoimmune-type of MHN
(type 4 or 5; 42%), and lymphoid aggregates (32%).
Concurrence of autoimmune features was frequent,
with two features noted in 15 (21%), three features in
19 (26%), and all four features in 14 (19%) sections.
No features of autoimmunity were observed in 21
(29%) sections. The presence of an autoimmune type
of MHN (4 or 5), lymphoid aggregates, and plasma
cell enrichment of inflammation was highly predictive
of the concurrence of central perivenulitis (in 93%,
87%, and 100%, respectively).
Correlation of Proposed Histological Features of
AI-ALF With Clinical Features of AIH and ALF. As
evidence that the four proposed histological features of
AI-ALF represented an autoimmune etiology, we com-
pared the individual features of autoimmunity with
well-recognized clinical and laboratory features of AIH
and with specific features of ALF known to vary by
etiology (Table 3). Individually, histological features of
AI-ALF except for the type of MHN were more fre-
quently observed with certain clinical markers of AIH.
The presence of lymphoid aggregates was associated
with lower alkaline phosphatase (156 6 25 versus 229
6 18 IU/L, respectively; P ¼ 0.02) and admission bil-
irubin (20.2 6 2.3 versus 26.9 6 1.6 mg/dL, respec-
tively; P ¼ 0.02), compared to biopsies without
lymphoid aggregates. Lower alkaline phosphatase is a
criterion favoring AIH according to the IAIHG.3 The
presence of central perivenulitis or plasma cell enrich-
ment of inflammation was noted in patients with a
more chronic clinical course (longer jaundice-to-ence-
phalopathy interval [JEI]) than in patients without
these features (20 6 3 versus 11 6 4 days,
Table 2. Prevalence and Concurrence of Proposed Histological Features of Autoimmunity in 72 Liver Specimens from
Patients with ALF
Histological Feature of AI-ALF
Type 4 or 5 Massive

















Type 4 or 5 MHN (%) – – 65** 31 60† 8 60† 11
Lymphoid aggregates (%) 50** 19 – – 43** 12 42* 15
Central perivenulitis (%) 93† 45 87** 55 – – 100† 7
Plasma cell enrichment (%) 90† 43 83* 53 96† 0 – –
Histological diagnosis of AI-ALF (%) 93† 33 83** 47 87† 4 87† 11
*P  0.05, **P < 0.01, ***P < 0.001, †P < 0.0001 versus ‘‘absent’’ group.
Table 3. Proposed Histological Features of AI-ALF Versus Clinical and Laboratory Characteristics of AIH and ALF
Clinical Characteristic
Histological Feature of AI-ALF
Type 4 or 5 Massive

















Female sex (%) 60 57 65 55 60 56 60 56
Jaundice-to-coma (days) 20 6 3 14 6 3 18 6 4 16 6 3 20 6 3* 11 6 4 21 6 3* 10 6 3
Admission INR 3.1 6 0.4 3.3 6 0.3 3.3 6 0.4 3.2 6 0.3 3.4 6 0.3 2.9 6 0.4 3.4 6 0.3 2.9 6 0.4
Peak creatinine (mg/dL) 2.3 6 0.4 2.7 6 0.3 2.3 6 0.4 2.7 6 0.3 2.2 6 0.3 3.1 6 0.4 2.2 6 0.3 3.1 6 0.4
Admission bilirubin (mg/dL) 23.9 6 2.1 25.3 6 1.8 20.2 6 2.3* 26.9 6 1.6 24.8 6 1.7 24.7 6 2.3 24.3 6 1.7 25.4 6 2.2
Admission alanine aminotransferase (IU/L) 1075 6 213 1193 6 180 915 6 241 1252 6 165 991 6 167 1432 6 229 984 6 171 1411 6 221
Admission alkaline phosphatase (IU/L) 215 6 23 198 6 20 156 6 25* 229 6 18 200 6 18 215 6 26 193 6 19 225 6 25
Admission globulins (g/dL) 3.7 6 0.2 3.2 6 0.2 3.7 6 0.3 3.2 6 0.2 3.5 6 0.2 3.2 6 0.3 3.6 6 0.2 3.1 6 0.3
ANA 6 ASMA (%) 72 56 77 56 70 50 68 54
Overall survival (%) 80 64 74 69 83** 48 82** 52
Liver transplantation (%) 60 59 57 61 72** 36 72** 37
Hepatitis in follow-up (%) 47 42 42 47 48 25 50 20
Overall survival and liver transplantation refers to cumulative rates at 21 days from admission.
*P  0.05, **P < 0.01, ***P < 0.001, †P < 0.0001 versus ‘‘absent’’ group.
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respectively; P ¼ 0.032 and 21 6 3 versus 10 6 3
days, respectively; P ¼ 0.015), also a feature of AIH.
Perhaps as a result of this more prolonged course,
overall survival was significantly higher in patients
with central perivenulitis and plasma cell enrichment
than in those without these features (83 versus 48%,
respectively; P ¼ 0.003 and 82 versus 52%, respec-
tively; P ¼ 0.008) due to an increased rate of liver
transplantation (72 versus 36%, respectively; P ¼
0.005 and 72 versus 37%, respectively; P ¼ 0.003).
There was no difference in transplant-free survival in
the presence or absence of any histological feature,
although the number of spontaneous survivors was
small (N ¼ 11; data not shown). Although all four
proposed histological features of AI-ALF were more
frequently observed in patients with classical features
of AIH (female sex, presence of ANA and/or ASMA,
and higher serum globulins), none reached statistical
significance.
Correlation of Clinicopathological Schemes of
Diagnosing AI-ALF with Classical Features of AIH
and Clinical Features of ALF. Although individual
histological features of AI-ALF were weakly associated
with clinical features of autoimmunity, an overall histo-
logical diagnosis of probable AI-ALF conferred a discrimi-
nating clinical phenotype of autoimmunity as compared
to those without probable AI-ALF (Table 4). Patients
with a histological diagnosis of probable AI-ALF had a
more subclinical course (JEI of 21 6 3 versus 11 6 3
days; P ¼ 0.024), milder degree of renal failure (peak cre-
atinine 2.1 6 0.3 versus 3.2 6 0.4 mg/dL; P ¼ 0.025),
lower admission alanine aminotransferase (921 6 125
versus 14566 207 IU/L; P ¼ 0.053), higher serum glob-
ulins (3.7 6 0.2 versus 3.0 6 0.2 g/dL; P ¼ 0.037),
higher prevalence of ANA and/or ASMA (73 versus 48%;
P¼ 0.034), and higher 21-day survival (86 versus 50%; P
¼ 0.002). Because the diagnosis of AIH also relies on lab-
oratory markers of autoimmunity, we also examined the
ability of ANA and/or ASMA and serum globulins to
improve the identification of an autoimmune phenotype
beyond histology alone (Table 4). The addition of ANA
and/or ASMA to the histological diagnosis of probable
AI-ALF better identified a population with a classical
AIH phenotype, in that patients were also predominantly
female (72 versus 48%; P < 0.05), had higher serum
globulins (3.9 6 0.2 versus 3.0 6 0.2 g/dL, respectively;
P < 0.005), and a higher incidence of hepatitis in long-
term follow-up (67 versus 17%, respectively; P ¼ 0.019)
compared to those without concordant histology for
probable AI-ALF and the presence of autoantibodies.
Similarly, the subgroup of patients with higher SDC
for AIH scores (6), which takes into account histology,
globulins, and autoantibodies, also more closely
resembled patients with classical AIH, although the
incidence of hepatitis in follow-up was not statistically
different from patients with low SDC scores (<6).
Specificity of AI-ALF Histology Index in Patients
with Defined Etiologies. Because liver biopsies are less
likely to be performed in patients with ALF of defined
etiology and OLT is infrequently performed for APAP-
induced ALF, only a limited number of tissue samples
were available to test the specificity of the 4 proposed
features of AI-ALF against other etiologies. Specimens
from 16 subjects, nine with APAP-induced ALF, five
with hepatitis B virus (HBV)-induced ALF, and two
with hepatitis A virus (HAV)-induced ALF were





AI-ALF and ANA 6 ASMA
Simplified Diagnostic Criteria for













Female sex (%) 62 53 73* 48 69 51
Jaundice-to-coma (days) 22 6 3* 11 6 3 21 6 3 14 6 3 22 6 3* 13 6 3
Admission INR 3.1 6 0.3 3.4 6 0.4 2.9 6 0.4 3.5 6 0.3 3.1 6 0.4 3.3 6 0.3
Peak creatinine (mg/dL) 2.1 6 0.3* 3.2 6 0.4 2.2 6 0.3 2.7 6 0.3 2.2 6 0.4 2.7 6 0.3
Admission bilirubin (mg/dL) 25.4 6 1.8 27.8 6 2.1 24.1 6 2.1 24.7 6 2.8 25.3 6 2.1 24.3 6 2.7
Alanine aminotransferase on admission (IU/L) 921 6 175* 1456 6 207 851 6 210* 1393 6 181 936 6 214 1284 6 176
Admission alkaline phosphatase (IU/L) 192 6 19 224 6 23 190 6 23 221 6 20 196 6 24 211 6 20
Admission globulins (g/dL) 3.7 6 0.2* 3.0 6 0.2 3.9 6 0.2** 3.0 6 0.2 4.3 6 0.2† 2.7 6 0.2
ANA 6 ASMA (%) 73* 48 100† 35 93† 42
Overall survival (%) 86** 50 87* 60 86* 61
Hepatitis in follow-up (%) 52 17 67** 17 60 25
Overall survival refers to cumulative rates at 21 days from admission. SDC for AIH pertain to a composite score based on histology, presence of autoantibodies,
serum globulin concentrations, and the absence of hepatitis viral markers, as described by Hennes et al.4
*P  0.05, **P < 0.01, †P < 0.0001 versus ‘‘absent’’ group.
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assessed in a blinded fashion as described above. All
five of the sections from patients with HBV-ALF were
characterized by central perivenulitis typically with
lymphoid aggregates. In contrast, seven of nine speci-
mens with APAP-ALF and both of those from HAV-
ALF were deemed not compatible with AI-ALF. Sec-
tions from two other patients with APAP-ALF showed
plasma cell-predominant inflammation and central
perivenulitis, three had MHN4, and one had lymph-
oid aggregates (data not shown).
Discussion
The identification of a potentially reversible etiology
of ALF, such as AI-ALF, is a primary goal in manage-
ment. However, the absence of a formal classification
system based upon morphology remains a major obsta-
cle. A broad range of terms has been used to describe
the MHN of ALF, including ‘‘map-like’’,18 ‘‘zonal,’’ or
‘‘panlobular’’,19 changes interpreted as nonspecific.
Therefore, this study focused on characterizing specific
patterns of MHN as well as other specific histological
features which favor an autoimmune pathogenesis.
In contrast to classical AIH, there are no consensus
guidelines to distinguish AI-ALF from other etiologies
of ALF. Moreover, adequate numbers of patients with
ALF and liver histology are not available to prospec-
tively test our observations, even within a large
research consortium devoted to the study of ALF.
Consequently, we analyzed our observations in terms
of their ability to identify a classical autoimmune phe-
notype assuming the phenotype for patients with AIH
is similar to patients with AI-ALF. We found that the
four histological features proposed to represent AI-ALF
are common in patients with ALF of indeterminate eti-
ology, and that the features usually occur concurrently
in the same liver specimen (Table 2). Although certain
histological features of autoimmunity are associated
with clinical features suggestive of AIH (Table 3), an
overall histological impression of AI-ALF is associated
with a decidedly autoimmune phenotype (subacute clin-
ical course, higher globulins, higher prevalence of auto-
antibodies; Table 4). Furthermore, the addition of ANA
and/or ASMA to a histological diagnosis of probable
AI-ALF appears to strengthen this autoimmune pheno-
type to include a predominantly female population with
a higher incidence of hepatitis in long-term follow-up
(Table 4). The SDC for AIH, which identified 24%
of patients with nonacetaminophen ALF as having pos-
sible or probable AIH in a recent study,20 did not
appear to improve the identification of patients with an
autoimmune phenotype over concordance for final his-
tological diagnosis of AI-ALF and the presence of ANA
and/or ASMA.
Classical histological features of nonfulminant AIH
include a portal tract–based necroinflammatory process
with interface hepatitis, often with lobular (zone 2
and 3) involvement1,21,22; centrilobular predominance is
distinctly unusual. A centrilobular variant of AIH first
proposed by Pratt et al.6 was followed by several other
case reports and small series,7-12 suggesting that the cen-
trilobular variant represents an early, severe or acute pre-
sentation of AIH, which may either evolve into the clas-
sical portal-based hepatitis or remain centrilobular.11,12
In the largest series to date, 20 of 114 (18%) of liver
biopsies from classical AIH patients (none with ALF)
had predominantly centrilobular necroinflammation,
four of whom had exclusive centrilobular disease.11
Patients with the centrilobular variant more often pre-
sented as an acute hepatitis, had higher hepatic activity
indices, and had less fibrosis than did the classical portal-
based variants; centrilobular hemorrhage resembling he-
patic venous outflow obstruction (MHN4 in the present
work) has also been noted.12 Although these reports
described patients with acute AIH without ALF, a few
subsequent cases of ALF considered likely autoimmune
feature central perivenulitis as the histological hallmark of
severe, immune-mediated liver injury.8,9
The individual histological features of autoimmunity
are not entirely specific to AI-ALF. Although the 16
liver specimens from patients with ‘‘defined’’ etiology
exhibited fewer features of autoimmunity, those from
all five patients with HBV-ALF and two of nine from
APAP-ALF were characterized by at least some autoim-
mune features. Several explanations are plausible, includ-
ing more than one etiology, misdiagnosis, similar immu-
nopathogenesis, or evolution from an early metabolite-
mediated necrosis to a lymphocyte-plasma cell mediated
injury following exposure of autoantigens. A similar
immunopathogenesis between AI-ALF and HBV-induced
ALF seems likely, as overwhelming viral infections are
known to activate B lymphocytes to differentiate into
plasma cells secreting immunoglobulin M (IgM) and
IgG against the hepatitis B core antigen.23,24 Moreover,
despite the classical description of APAP-induced hepato-
toxicity as bland centrilobular necrosis, the innate
immune system also participates in liver injury.25 It
should be emphasized that the aim of the current
study was to identify AI-ALF among subjects with
indeterminate etiology, and no single test, including
liver histology, is capable of cinching the diagnosis; AI-
ALF remains a diagnosis based on exclusion of viral and
drug etiologies first, but also requires histological and
serological evaluation. Although liver biopsies are not
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performed routinely in ALF due to bleeding risk, our
observations suggest that the information provided by
histology may be worth the risk in indeterminate cases.
It remains unclear whether the centrilobular variant
of AIH represents the same or a different disease as
the classical portal-based variant. Perivenulitis and cen-
trilobular necrosis are also features of atypical liver al-
lograft rejection, which appears to be distinct from
classical, portal-based rejection in that it resists immu-
nosuppression and may presage chronic rejection.13
Liver allografts with centrilobular acute rejection can
also evolve into a state of veno-occlusive congestion
similar to the hemorrhagic MHN4 lesion noted in
many patients herein with AI-ALF.13,26,27 These histo-
logical and clinical features are distinct from classical
descriptions of acute allograft rejection.28 Hepatotoxicity
due to certain drugs can also target the centrilobular
region; halothane hepatitis, the best defined, results
from metabolic idiosyncrasy and autoantibody forma-
tion toward antigens located within pericentral hepato-
cytes.30 Therefore, it seems plausible that specific anti-
gens, whether environmental, drug-derived, or expressed
on non-self hepatocytes, may trigger an immune-medi-
ated injury to the centrilobular region by targeting anti-
gens preferentially expressed by zone three hepatocytes.
The fact that no true gold standard exists for the
diagnosis of AIH represents a limitation of our obser-
vations. Accordingly, we reasoned that patients with
bona fide AI-ALF would more often develop chronic
hepatitis in their native livers (in spontaneous survi-
vors) or allografts (in transplant recipients) than those
with indeterminate ALF. After 1-4 years follow-up, we
found a high (44%) incidence of hepatitis in the study
population, and those with histologically proven hepa-
titis were more frequently those with positive ANA 6
ASMA who were given a final histological diagnosis of
probable AI-ALF. These data seem further supported
by the fact that none of these markers of autoimmun-
ity before transplant were associated with allograft
rejection (data not shown).
The clinical relevance of non–organ specific autoanti-
bodies in ALF remains uncertain. A recent screen of ANA,
ASMA, AMA, and LKM autoantibodies in patients with
ALF revealed a prevalence of 25% in patients with non-
acetaminophen drug reactions and hepatotrophic viral
infections, but in none of patients with acetaminophen-
induced ALF,31 suggesting that their presence may nonspe-
cifically accompany overwhelming immune activation. Our
observations suggest that the presence of autoantibodies
correlate with histological diagnosis of AI-ALF. Specifi-
cally, patients with AI-ALF more frequently had ANA
and/or ASMA, and anti-LKM, anti-SLA, and anti-tTG
were exclusively detected in patients with histological
AI-ALF (data not shown). Moreover, the addition of
ANA 6 ASMA to a histological diagnosis of AI-ALF
appeared to improve the detection of histology alone to
identify an autoimmune phenotype.
In conclusion, we propose that four histological fea-
tures of autoimmune liver disease can be interpreted as
probable AI-ALF. Patients with probable AI-ALF on his-
tology have a distinctly autoimmune clinical phenotype,
and the presence of ANA and/or ASMA may improve
the distinction of AI-ALF from other cases of indetermi-
nate ALF. Similar to aggressive, refractory cases of acute
cellular allograft rejection, centrilobular necroinflamma-
tory features appear to be a hallmark of AI-ALF.
References
1. Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges.
Gastroenterology 2001;120:1502-1517.
2. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnick
GL, Elveback IR, et al. Clinical, biochemical, and histological remis-
sion of severe chronic active liver disease: a controlled study of treat-
ments and early prognosis. Gastroenterology 1972;63:820-833.
3. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL,
et al. International Autoimmune Hepatitis Group Report: review of crite-
ria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-938.
4. Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL,
et al. Simplified criteria for the diagnosis of autoimmune hepatitis.
HEPATOLOGY 2008;48:169-176.
5. Lee WM. Etiologies of acute liver failure. Semin Liver Dis 2008;28:
142-152.
6. Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel his-
tological lesion in glucocorticoid-responsive chronic hepatitis. Gastroen-
terology 1997;113:664-668.
7. Te HS, Koukoulis G, Ganger DR. Autoimmune hepatitis: a histological vari-
ant associated with prominent centrilobular necrosis. Gut 1997;41:269-271.
8. Abe M, Onji M, Kawai-Ninomiya K, Michitaka K, Matsuura B, Hiasa
Y, et al. Clinicopathologic features of the severe form of acute type 1
autoimmune hepatitis. Clin Gastroenterol Hepatol 2007;5:255-258.
9. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo
PY. Fulminant hepatic failure as the initial presentation of acute auto-
immune hepatitis. Clin Gastroenterol Hepatol 2004;2:625-631.
10. Singh R, Nair S, Farr G, Mason A, Perrillo R. Acute autoimmune hep-
atitis presenting with centrizonal liver disease: case report and review of
the literature. Am J Gastroenterol 2002;97:2670-2673.
11. Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular
necrosis in autoimmune hepatitis: a histological feature associated with
acute clinical presentation. J Clin Pathol 2006;59:246-249.
12. Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with
centrilobular necrosis. Am J Surg Pathol 2004;28:471-478.
13. Turlin B, Slapak GI, Hayllar KM, Heaton N, Williams R, Portmann
B. Centrilobular necrosis after orthotopic liver transplantation: a longi-
tudinal clinicopathologic study in 71 patients. Liver Transpl Surg 1995;
1:285-289.
14. Hubscher SG. Central perivenulitis: a common and potentially impor-
tant finding in late posttransplant liver biopsies. Liver Transpl 2008;14:
596-600.
15. Trey C, Davidson CS. The management of fulminant hepatic failure.
Prog Liver Dis 1970;3:282-298.
16. Abraham SC, Freese DK, Ishitani MB, Krasinskas AM, Wu TT. Signif-
icance of central perivenulitis in pediatric liver transplantation. Am J
Surg Pathol 2008;32:1479-1488.
HEPATOLOGY, Vol. 53, No. 2, 2011 STRAVITZ ET AL. 525
17. Leung PS, Rossaro L, Davis PA, Park O, Tanaka A, Kikuchi K, et al.
Antimitochondrial antibodies in acute liver failure: implications for pri-
mary biliary cirrhosis. HEPATOLOGY 2007;46:1436-1442.
18. Quaglia A, Portmann BC, Knisely AS, Srinivasan P, Muiesan P, Wendon
J, et al. Auxiliary transplantation for acute liver failure: Histopathological
study of native liver regeneration. Liver Transpl 2008;14:1437-1448.
19. Kirsch R, Yap J, Roberts EA, Cutz E. Clinicopathologic spectrum of
massive and submassive hepatic necrosis in infants and children. Hum
Pathol 2009;40:516-526.
20. Yeoman AD, Westbrook RH, Al-Chalabi T, Carey I, Heaton ND, Port-
mann BC, et al. Diagnostic value and utility of the simplified Interna-
tional Autoimmune Hepatitis Group (IAIHG) criteria in acute and
chronic liver disease. HEPATOLOGY 2009;50:538-545.
21. Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent-onset
autoimmune hepatitis. Biopsy findings and clinical correlations. Am J
Surg Pathol 1995;19:699-708.
22. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and
reporting. Am J Surg Pathol 1995;19:1409-1417.
23. Fink K, Manjarrez-Orduno N, Schildknecht A, Weber J, Senn BM, Zin-
kernagel RM, et al. B cell activation state-governed formation of germinal
centers following viral infection. J Immunol 2007;179:5877-5885.
24. Farci P, Diaz G, Chen Z, Govindarajan S, Tice A, Agulto L, et al. B
cell gene signature with massive intrahepatic production of antibodies
to hepatitis B core antigen in hepatitis B virus-associated acute liver
failure. Proc Natl Acad Sci U S A 2010;107:8766-8771.
25. Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a
critical role in determining the progression and severity of acetamino-
phen hepatotoxicity. Gastroenterology 2004;127:1760-1774.
26. Nakazawa Y, Jonsson JR, Walker NI, Kerlin P, Steadman C, Lynch SV,
et al. Fibrous obliterative lesions of veins contribute to progressive
fibrosis in chronic liver allograft rejection. HEPATOLOGY 2000;32:
1240-1247.
27. Sebagh M, Debette M, Samuel D, Emile JF, Falissard B, Cailliez V,
et al. ‘‘Silent’’ presentation of veno-occlusive disease after liver trans-
plantation as part of the process of cellular rejection with endothelial
predilection. HEPATOLOGY 1999;30:1144-1150.
28. . Banff schema for grading liver allograft rejection: an international
consensus document. HEPATOLOGY 1997;25:658-663.
29. Demetris AJ. Central venulitis in liver allografts: considerations of dif-
ferential diagnosis. HEPATOLOGY 2001;33:1329-1330.
30. Smith GC, Kenna JG, Harrison DJ, Tew D, Wolf CR. Autoantibodies
to hepatic microsomal carboxylesterase in halothane hepatitis. Lancet
1993;342:963-964.
31. Bernal W, Ma Y, Smith HM, Portmann B, Wendon J, Vergani D. The
significance of autoantibodies and immunoglobulins in acute liver fail-
ure: a cohort study. J Hepatol 2007;47:664-670.
526 STRAVITZ ET AL. HEPATOLOGY, February 2011
